SCHEMBL29680237

SCHEMBL29680237

CC(C)[Si](Oc1ccc2c(Br)c(F)ccc2c1)(C(C)C)C(C)C

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.31
NCEH1 Q6PIU2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29680425 0.82 MET (0.38) TRPA1
SCHEMBL31281958 0.80
SCHEMBL19641545 0.78 PARP1 (0.33)
SCHEMBL31680206 0.78 PARP1 (0.33)
SCHEMBL29080089 0.77
SCHEMBL31048910 0.76
SCHEMBL29080149 0.76
SCHEMBL190598 0.76 NCEH1 (0.47) NCEH1
SCHEMBL16717453 0.76 HTR2A (0.38) TRPA1
SCHEMBL17200284 0.74 SLC6A4 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 EP disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed